ANI Pharmaceuticals Stock News

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Finan

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President & Chief Executive O

ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Regenxbio (RGNX) delivered earnings and revenue surprises of -9.72% and 25.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on M

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.